VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Menstruating females 10-19 years of age            │ Menstruating females 10-19 years of age            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non-smoker                                         │ Non-smoker                                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Physician and patient have agreed to initiate      │ Physician and patient have agreed to initiate      │     100 │
│ Lysteda                                            │ Lysteda                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of HMB based on the medical judgment of  │ Diagnosis of HMB based on the medical judgment of  │     100 │
│ the principal or site investigator                 │ the principal or site investigator                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must report menstrual periods occurring   │ Subjects must report menstrual periods occurring   │     100 │
│ within 21-60 days from the start of one period to  │ within 21-60 days from the start of one period to  │         │
│ the start of the next menstrual period             │ the start of the next menstrual period             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative pregnancy test                            │ Negative pregnancy test                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed consent obtained and signed               │ Informed consent obtained and signed               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed assent obtained and signed                │ Informed assent obtained and signed                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Understanding of study procedures                  │ Understanding of study procedures                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to comply with study procedures for the    │ Ability to comply with study procedures for the    │     100 │
│ entire length of the study                         │ entire length of the study                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects should be either sexually inactive        │ Subjects should be either sexually inactive        │     100 │
│ (abstinent) or agree to use a barrier method with  │ (abstinent) or agree to use a barrier method with  │         │
│ spermicide in the event of sexual activity         │ spermicide in the event of sexual activity         │         │
│ throughout the study period                        │ throughout the study period                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active thromboembolic disease, history of          │ Active thromboembolic disease, history of          │     100 │
│ thromboembolic disease (including retinal vein or  │ thromboembolic disease (including retinal vein or  │         │
│ artery occlusion), known inherited thrombophilia,  │ artery occlusion), known inherited thrombophilia,  │         │
│ or family history of thrombosis in a first degree  │ or family history of thrombosis in a first degree  │         │
│ relative                                           │ relative                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject has a severe medical or psychiatric        │ Subject has a severe medical or psychiatric        │     100 │
│ illness that, in the opinion of the Investigator,  │ illness that, in the opinion of the Investigator,  │         │
│ would affect subject safety or compliance          │ would affect subject safety or compliance          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical evidence of severe bleeding disorder.     │ Clinical evidence of severe bleeding disorder.     │     100 │
│ Patients with mild bleeding disorders such as type │ Patients with mild bleeding disorders such as type │         │
│ 1 von Willebrand disease, mild platelet function   │ 1 von Willebrand disease, mild platelet function   │         │
│ defects such as platelet storage pool or release   │ defects such as platelet storage pool or release   │         │
│ defects, and patients with bleeding due to Ehlers  │ defects, and patients with bleeding due to Ehlers  │         │
│ Danlos syndrome WILL be eligible to participate in │ Danlos syndrome WILL be eligible to participate in │         │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy within the past 6 months and/or breast-  │ Pregnancy within the past 6 months and/or breast-  │     100 │
│ feeding                                            │ feeding                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of hormonal contraception (estrogen and        │ Use of hormonal contraception (estrogen and        │     100 │
│ progestin) within 3 months of study entry, or      │ progestin) within 3 months of study entry, or      │         │
│ anticipated need to initiate estrogen-containing   │ anticipated need to initiate estrogen-containing   │         │
│ hormonal contraception during the study period     │ hormonal contraception during the study period     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of systemic steroids within 1 month of study   │ Use of systemic steroids within 1 month of study   │     100 │
│ entry                                              │ entry                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of subarachnoid hemorrhage                 │ History of subarachnoid hemorrhage                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of Hepatitis B, C, or HIV                  │ History of Hepatitis B, C, or HIV                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of intranasal DDAVP during menses will be      │ Use of intranasal DDAVP during menses will be      │     100 │
│ permitted, but only if the patient has a history   │ permitted, but only if the patient has a history   │         │
│ of using DDAVP consistently for ≥3 menstrual       │ of using DDAVP consistently for ≥3 menstrual       │         │
│ cycles prior to study enrollment, so that change   │ cycles prior to study enrollment, so that change   │         │
│ in menstrual blood loss due to addition of Lysteda │ in menstrual blood loss due to addition of Lysteda │         │
│ can be assessed. Use of one-time DDAVP during a    │ can be assessed. Use of one-time DDAVP during a    │         │
│ DDAVP/Stimate challenge is also permitted during   │ DDAVP/Stimate challenge is also permitted during   │         │
│ the study period, as is use of DDAVP in the event  │ the study period, as is use of DDAVP in the event  │         │
│ of severe epistaxis, trauma, or surgical           │ of severe epistaxis, trauma, or surgical           │         │
│ procedures during the study period                 │ procedures during the study period                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic blood pressure \<85 or diastolic blood    │ Systolic blood pressure <85 or diastolic blood     │      98 │
│ pressure \<55                                      │ pressure <55                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Baseline creatinine \>20% above the upper limit of │ Baseline creatinine >20% above the upper limit of  │      99 │
│ normal for age                                     │ normal for age                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe anemia (hemoglobin \<8 g/dL)                │ Severe anemia (hemoglobin <8 g/dL)                 │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Heart rate \<50 at time of screening               │ Heart rate <50 at time of screening                │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                           │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════════╪═════════╡
│ Must be FEMALE                    │ Informed consent obtained and signed    │      24 │
├───────────────────────────────────┼─────────────────────────────────────────┼─────────┤
│ Must have maximum age of 19 Years │ Menstruating females 10-19 years of age │      44 │
├───────────────────────────────────┼─────────────────────────────────────────┼─────────┤
│ Must have minimum age of 10 Years │ Menstruating females 10-19 years of age │      47 │
╘═══════════════════════════════════╧═════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 92.96296296296296
OverAll Ratio: 95.48148148148148
